This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

JNJ-4178

Johnson & Johnson

Drug Names(s): AL-335/ACH-3102/TMC-435, 3DAA, AL-335/Odalasvir/Simeprevir

Description: AL-335/Odalasvir/Simeprevir is a fixed dose combination of an uridine based nucleotide analog polymerase inhibitor AL-335, the second generation NS5A inhibitor odalasvir, and the NS3/4A protease inhibitor simeprevir.

Deal Structure: Medivir and Tibotec
In November 2004, Medivir signed a license and research collaboration agreement on Hepatitis C with Tibotec Pharmaceuticals, a subsidiary of Johnson & Johnson. The goal of the research collaboration is to discover and develop orally active protease inhibitors of the NS3/4A protease of HCV. Tibotec will be responsible for the global clinical development of these compounds and has acquired exclusive, worldwide marketing rights, except for in the Nordic countries, which have been retained by Medivir. The product will be commercialized in the non-Nordic countries by the Tibotec, Ortho-Biotech or Janssen Cilag operating companies of Johnson & Johnson.

Under the terms of the agreement, Tibotec will make an upfront payment of Euro 6.5 million and, based on successful achievement of pre-specified scientific, clinical and regulatory milestones, payments of up to Euro 62 million. In addition, upon reaching a specific clinical milestone, Medivir has the right...See full deal structure in Biomedtracker

Partners: Achillion Pharmaceuticals, Inc. Medivir AB


JNJ-4178 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug